RGBP - Regen BioPharma up 21% to reach near three-month high after patent filing

• The shares of nanocap biotech Regen BioPharma ( OTCPK:RGBP ) surged 21% on Wednesday to reach the highest level since May after the company announced the submission of a U.S. patent application related to a mRNA cancer immunotherapeutic vaccine.
• The provisional patent application covers the use of dendritic cell technologies to enhance the company’s patented survivin mRNA cancer immunotherapeutic vaccine, Regen ( OTCPK:RGBP ) said.
• "The currently filed application discloses means of significantly increasing efficacy by combining modified-mRNA with unique cellular immunotherapy as well as adjuvant approaches,” Chief Executive Dr. David Koos remarked.
• In 2021, the U.S. Patent and Trademark Office awarded the patent # 11,090,332 for Regen ( OTCPK:RGBP ), covering the IP rights related to the composition of matter of survivin modified-mRNA useful for training the immune system to destroy cancer.

For further details see: